Published in Nature on November 12, 2009
Therapeutic antibody targeting of individual Notch receptors. Nature (2010) 4.56
Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol (2010) 4.22
The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest (2012) 3.09
ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature (2010) 2.65
Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J Pathol (2010) 2.58
Translating p53 into the clinic. Nat Rev Clin Oncol (2010) 2.55
Targeting Notch to target cancer stem cells. Clin Cancer Res (2010) 2.46
Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. Science (2011) 2.36
Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc Natl Acad Sci U S A (2013) 2.22
Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov (2014) 2.20
Inhibition of α-helix-mediated protein-protein interactions using designed molecules. Nat Chem (2013) 2.02
Inhibition of oncogenic Wnt signaling through direct targeting of β-catenin. Proc Natl Acad Sci U S A (2012) 1.98
Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther (2013) 1.96
Deletion-based mechanisms of Notch1 activation in T-ALL: key roles for RAG recombinase and a conserved internal translational start site in Notch1. Blood (2010) 1.92
Plasma Hsp90 Level as a Marker of Early Acute Lymphoblastic Leukemia Engraftment and Progression in Mice. PLoS One (2015) 1.92
An orthosteric inhibitor of the Ras-Sos interaction. Nat Chem Biol (2011) 1.91
Interfacial inhibitors: targeting macromolecular complexes. Nat Rev Drug Discov (2011) 1.80
A complex task? Direct modulation of transcription factors with small molecules. Curr Opin Chem Biol (2010) 1.75
Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat Chem Biol (2013) 1.75
Systems approaches to polypharmacology and drug discovery. Curr Opin Drug Discov Devel (2010) 1.74
From fly wings to targeted cancer therapies: a centennial for notch signaling. Cancer Cell (2014) 1.70
Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res (2011) 1.65
p53-based cancer therapy. Cold Spring Harb Perspect Biol (2010) 1.62
Hydrocarbon-stapled peptides: principles, practice, and progress. J Med Chem (2014) 1.61
Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts. Blood (2014) 1.60
Reawakening fetal hemoglobin: prospects for new therapies for the β-globin disorders. Blood (2012) 1.58
The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance. Clin Cancer Res (2010) 1.58
Notch inhibitors for cancer treatment. Pharmacol Ther (2013) 1.55
Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner. Nat Med (2011) 1.55
Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev (2010) 1.54
Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice. J Clin Invest (2011) 1.51
Notch activity modulates the responsiveness of neural progenitors to sonic hedgehog signaling. Dev Cell (2015) 1.50
Deletion of the RNA-binding proteins ZFP36L1 and ZFP36L2 leads to perturbed thymic development and T lymphoblastic leukemia. Nat Immunol (2010) 1.49
Evaluation of diverse α/β-backbone patterns for functional α-helix mimicry: analogues of the Bim BH3 domain. J Am Chem Soc (2011) 1.49
The switch from fetal to adult hemoglobin. Cold Spring Harb Perspect Med (2013) 1.47
Assessing helical protein interfaces for inhibitor design. J Am Chem Soc (2011) 1.46
Objective assessment of cancer genes for drug discovery. Nat Rev Drug Discov (2013) 1.34
Emerging roles of TEAD transcription factors and its coactivators in cancers. Cancer Biol Ther (2013) 1.34
Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. Genes Cancer (2010) 1.33
D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms. Proc Natl Acad Sci U S A (2010) 1.29
Systematic analysis of helical protein interfaces reveals targets for synthetic inhibitors. ACS Chem Biol (2010) 1.29
Targeting protein-protein interactions as an anticancer strategy. Trends Pharmacol Sci (2013) 1.29
How chemoproteomics can enable drug discovery and development. Chem Biol (2012) 1.27
Getting in shape: controlling peptide bioactivity and bioavailability using conformational constraints. ACS Chem Biol (2012) 1.26
Osteosclerosis owing to Notch gain of function is solely Rbpj-dependent. J Bone Miner Res (2010) 1.25
Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition. Onco Targets Ther (2013) 1.23
Expanding the number of 'druggable' targets: non-enzymes and protein-protein interactions. Chem Biol Drug Des (2013) 1.21
Notch inhibition as a promising new approach to cancer therapy. Adv Exp Med Biol (2012) 1.20
High specificity in protein recognition by hydrogen-bond-surrogate α-helices: selective inhibition of the p53/MDM2 complex. Chembiochem (2010) 1.19
Therapeutic strategies to inhibit MYC. Cold Spring Harb Perspect Med (2014) 1.19
Emerging topics in Reelin function. Eur J Neurosci (2010) 1.17
Therapeutic approaches to modulating Notch signaling: current challenges and future prospects. Semin Cell Dev Biol (2012) 1.17
Structure-Based Design of Inhibitors of Protein-Protein Interactions: Mimicking Peptide Binding Epitopes. Angew Chem Int Ed Engl (2015) 1.17
Inhibition of Notch signaling by a γ-secretase inhibitor attenuates hepatic fibrosis in rats. PLoS One (2012) 1.16
Structural basis for cyclic Py-Im polyamide allosteric inhibition of nuclear receptor binding. J Am Chem Soc (2010) 1.15
Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex. Blood (2013) 1.15
Drugging the undruggable: transcription therapy for cancer. Biochim Biophys Acta (2012) 1.14
Bridged beta(3)-peptide inhibitors of p53-hDM2 complexation: correlation between affinity and cell permeability. J Am Chem Soc (2010) 1.14
Common threads in cardiac fibrosis, infarct scar formation, and wound healing. Fibrogenesis Tissue Repair (2012) 1.12
Design of triazole-stapled BCL9 α-helical peptides to target the β-catenin/B-cell CLL/lymphoma 9 (BCL9) protein-protein interaction. J Med Chem (2012) 1.12
Photoreactive stapled BH3 peptides to dissect the BCL-2 family interactome. Chem Biol (2010) 1.11
Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia. Mol Cancer Ther (2012) 1.09
DDX5 is a positive regulator of oncogenic NOTCH1 signaling in T cell acute lymphoblastic leukemia. Oncogene (2012) 1.06
Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of Notch signaling in cancer. Mol Ther (2011) 1.05
Notch regulation of bone development and remodeling and related skeletal disorders. Calcif Tissue Int (2011) 1.05
Essential biological processes of an emerging pathogen: DNA replication, transcription, and cell division in Acinetobacter spp. Microbiol Mol Biol Rev (2010) 1.04
Current views on the role of Notch signaling and the pathogenesis of human leukemia. BMC Cancer (2011) 1.03
Plucking the high hanging fruit: a systematic approach for targeting protein-protein interactions. Bioorg Med Chem (2012) 1.03
Notch signaling expands a pre-malignant pool of T-cell acute lymphoblastic leukemia clones without affecting leukemia-propagating cell frequency. Leukemia (2012) 1.03
AKAPs: the architectural underpinnings of local cAMP signaling. J Mol Cell Cardiol (2011) 1.02
Synthesis of cell-permeable stapled peptide dual inhibitors of the p53-Mdm2/Mdmx interactions via photoinduced cycloaddition. Bioorg Med Chem Lett (2011) 1.01
Notch signaling in lung cancer. Expert Rev Anticancer Ther (2011) 1.00
Notch signaling in skeletal health and disease. Eur J Endocrinol (2013) 1.00
Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease. Blood (2011) 0.99
Delta-like ligand 4 regulates central nervous system T cell accumulation during experimental autoimmune encephalomyelitis. J Immunol (2011) 0.99
Evolving the use of peptides as components of biomaterials. Biomaterials (2011) 0.99
NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications. Breast Cancer Res (2011) 0.99
Antiviral activity of α-helical stapled peptides designed from the HIV-1 capsid dimerization domain. Retrovirology (2011) 0.99
Embryonic signaling pathways and rhabdomyosarcoma: contributions to cancer development and opportunities for therapeutic targeting. Sarcoma (2012) 0.99
Notch signaling in prostate cancer: a moving target. Prostate (2014) 0.98
Discovery of a potent stapled helix peptide that binds to the 70N domain of replication protein A. J Med Chem (2014) 0.97
Evolution: a guide to perturb protein function and networks. Curr Opin Struct Biol (2010) 0.97
Identification of epidermal Pdx1 expression discloses different roles of Notch1 and Notch2 in murine Kras(G12D)-induced skin carcinogenesis in vivo. PLoS One (2010) 0.97
T. gondii RP promoters & knockdown reveal molecular pathways associated with proliferation and cell-cycle arrest. PLoS One (2010) 0.96
Protein domain mimetics as in vivo modulators of hypoxia-inducible factor signaling. Proc Natl Acad Sci U S A (2013) 0.96
Impact of notch signaling on inflammatory responses in cardiovascular disorders. Int J Mol Sci (2013) 0.96
DUX4 recruits p300/CBP through its C-terminus and induces global H3K27 acetylation changes. Nucleic Acids Res (2016) 0.96
Notch-mediated patterning and cell fate allocation of pancreatic progenitor cells. Development (2012) 0.96
A left-handed solution to peptide inhibition of the p53-MDM2 interaction. Angew Chem Int Ed Engl (2010) 0.96
Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer. Clin Cancer Res (2014) 0.95
Notching on Cancer's Door: Notch Signaling in Brain Tumors. Front Oncol (2015) 0.95
Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis Rheum (2011) 0.94
The NOTCH signaling pathway: role in the pathogenesis of T-cell acute lymphoblastic leukemia and implication for therapy. Ther Adv Hematol (2013) 0.94
In vitro selection of highly modified cyclic peptides that act as tight binding inhibitors. J Am Chem Soc (2012) 0.94
On-resin peptide macrocyclization using thiol-ene click chemistry. Chem Commun (Camb) (2010) 0.94
Hajdu-Cheney syndrome: a review. Orphanet J Rare Dis (2014) 0.93
Late SV40 factor: a key mediator of Notch signaling in human hepatocarcinogenesis. World J Gastroenterol (2011) 0.93
Notch signaling in developmental and tumor angiogenesis. Genes Cancer (2011) 0.93
Broadly applicable methodology for the rapid and dosable small molecule-mediated regulation of transcription factors in human cells. J Am Chem Soc (2013) 0.92
HES1 (hairy and enhancer of split 1) is a determinant of bone mass. J Biol Chem (2010) 0.92
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Notch signaling: cell fate control and signal integration in development. Science (1999) 28.83
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 18.84
Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol (2006) 13.12
A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature (1999) 10.36
TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell (1991) 10.06
Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature (1996) 8.02
Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science (2004) 7.63
Transcription factors as targets for cancer therapy. Nat Rev Cancer (2002) 7.27
NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A (2006) 6.80
Notch1 functions as a tumor suppressor in mouse skin. Nat Genet (2003) 6.76
Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nat Genet (1997) 6.66
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med (2007) 6.55
Mutations in NOTCH1 cause aortic valve disease. Nature (2005) 6.27
c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev (2006) 6.19
Notch signals control the fate of immature progenitor cells in the intestine. Nature (2005) 6.13
Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell (2003) 5.36
Presenilin is required for activity and nuclear access of Notch in Drosophila. Nature (1999) 4.64
FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med (2007) 4.59
Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem (2001) 4.45
Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol Cell Biol (2003) 4.43
Structural basis for cooperativity in recruitment of MAML coactivators to Notch transcription complexes. Cell (2006) 4.28
Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med (2008) 3.98
Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol (2004) 3.87
Notch4/int-3, a mammary proto-oncogene, is an endothelial cell-specific mammalian Notch gene. Development (1996) 3.84
MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors. Nat Genet (2000) 3.82
The suppressor of hairless protein participates in notch receptor signaling. Cell (1994) 3.81
Crystal structure of the CSL-Notch-Mastermind ternary complex bound to DNA. Cell (2006) 3.42
Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27Kip1 and p57Kip2. EMBO Rep (2008) 3.03
Neurogenic phenotypes and altered Notch processing in Drosophila Presenilin mutants. Nature (1999) 2.99
Mastermind critically regulates Notch-mediated lymphoid cell fate decisions. Blood (2004) 2.90
Essential roles for ankyrin repeat and transactivation domains in induction of T-cell leukemia by notch1. Mol Cell Biol (2000) 2.80
Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J Clin Invest (2008) 2.73
Notch3 gene amplification in ovarian cancer. Cancer Res (2006) 2.66
Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res (2007) 2.54
Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood (2003) 2.41
Presenilin-1 and -2 are molecular targets for gamma-secretase inhibitors. J Biol Chem (2000) 2.33
Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling. Chem Biol (2007) 2.02
Structural requirements for assembly of the CSL.intracellular Notch1.Mastermind-like 1 transcriptional activation complex. J Biol Chem (2003) 2.02
Mastermind is a putative activator for Notch. Curr Biol (2000) 1.69
MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment. Leukemia (2007) 1.57
Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. Cancer Res (2009) 1.54
Mutational and energetic studies of Notch 1 transcription complexes. J Mol Biol (2007) 1.35
A novel noninvasive model of endometriosis for monitoring the efficacy of antiangiogenic therapy. Am J Pathol (2006) 1.03
Activity of gamma-secretase on substrates other than APP. Curr Top Med Chem (2008) 0.99
An improved beta-lactamase reporter assay: multiplexing with a cytotoxicity readout for enhanced accuracy of hit identification. J Biomol Screen (2007) 0.89
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 18.84
Selective inhibition of BET bromodomains. Nature (2010) 18.79
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med (2002) 14.01
FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell (2007) 12.33
Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes Dev (2005) 12.15
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med (2003) 11.17
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood (2004) 11.07
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 10.60
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell (2007) 8.94
Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell (2013) 8.37
Transcriptional amplification in tumor cells with elevated c-Myc. Cell (2012) 8.24
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med (2007) 8.18
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell (2005) 7.99
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med (2006) 7.95
Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science (2004) 7.63
HDAC2 negatively regulates memory formation and synaptic plasticity. Nature (2009) 6.96
Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature (2008) 6.80
NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A (2006) 6.80
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell (2002) 6.64
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 6.55
c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev (2006) 6.19
Regulation of MLL1 H3K4 methyltransferase activity by its core components. Nat Struct Mol Biol (2006) 6.03
MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell (2004) 5.98
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood (2006) 5.95
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood (2009) 5.72
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal (2009) 5.57
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res (2007) 5.45
H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell (2008) 5.23
Drug development and clinical trials--the path to an approved cancer drug. Nat Rev Clin Oncol (2012) 4.98
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell (2011) 4.90
A base-excision DNA-repair protein finds intrahelical lesion bases by fast sliding in contact with DNA. Proc Natl Acad Sci U S A (2006) 4.60
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell (2011) 4.56
Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet (2007) 4.52
Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol Cell Biol (2003) 4.43
Structural basis for cooperativity in recruitment of MAML coactivators to Notch transcription complexes. Cell (2006) 4.28
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science (2013) 4.20
Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol (2011) 4.06
Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med (2002) 4.04
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med (2010) 4.00
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer (2007) 3.89
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood (2006) 3.88
A stapled BID BH3 helix directly binds and activates BAX. Mol Cell (2006) 3.86
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A (2005) 3.86
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood (2004) 3.84
The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell (2007) 3.79
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell (2003) 3.75
Drug therapy for acute myeloid leukemia. Blood (2005) 3.74
A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A (2003) 3.72
SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature (2011) 3.69
BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol (2005) 3.68
Structure of a repair enzyme interrogating undamaged DNA elucidates recognition of damaged DNA. Nature (2005) 3.67
Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell (2013) 3.63
Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med (2004) 3.55
Small-molecule inhibition of BRDT for male contraception. Cell (2012) 3.50
Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest (2004) 3.47
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood (2005) 3.47
Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell (2010) 3.46
Myeloproliferative disorders. Blood (2008) 3.37
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood (2009) 3.37
Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood (2005) 3.32
Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet (2002) 3.31
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood (2008) 3.30
Structural basis for removal of adenine mispaired with 8-oxoguanine by MutY adenine DNA glycosylase. Nature (2004) 3.30
Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. Proc Natl Acad Sci U S A (2002) 3.28
Notch signaling controls the generation and differentiation of early T lineage progenitors. Nat Immunol (2005) 3.26
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell (2004) 3.25
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell (2007) 3.23
Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science (2003) 3.21
Notch signaling in leukemia. Annu Rev Pathol (2008) 3.21
PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci U S A (2002) 3.19
Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer (2002) 3.18
Myc-induced T cell leukemia in transgenic zebrafish. Science (2003) 3.15
Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med (2006) 3.14
HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood (2008) 3.12
Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov (2013) 3.11
Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A (2011) 3.10
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet (2009) 3.10